US drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew of multibillion dollar takeovers in the biopharma sector this year. AbbVie is stumping up more ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

AbbVie is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net ...

Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates to reflect higher immunology sales after reviewing ...

CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging that AbbVie violated the Illinois Genetic ...

AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second slots, respectively, for the month, resuming the custom they upheld throughout most of 2024. Those gains over ...

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure ...

The approval has been granted to Vuity (formerly AGN-190584), a once-daily eyedrop formulation of muscarinic cholinergic agonist pilocarpine developed by ... smart watches. Allergan sees Vuity ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: March 14 at 7:58:28 PM EDT Loading Chart for ABBV ...